Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Operating Expenses (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Operating Expenses for 4 consecutive years, with $55.9 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 34.48% to $55.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $312.5 million through Dec 2025, down 3.77% year-over-year, with the annual reading at $312.5 million for FY2025, 3.77% down from the prior year.
  • Operating Expenses for Q4 2025 was $55.9 million at Phathom Pharmaceuticals, down from $58.6 million in the prior quarter.
  • The five-year high for Operating Expenses was $103.7 million in Q1 2025, with the low at $30.1 million in Q1 2023.
  • Average Operating Expenses over 4 years is $61.1 million, with a median of $57.2 million recorded in 2025.
  • The sharpest move saw Operating Expenses skyrocketed 162.6% in 2024, then tumbled 34.48% in 2025.
  • Over 4 years, Operating Expenses stood at $46.6 million in 2022, then soared by 50.92% to $70.4 million in 2023, then rose by 21.13% to $85.3 million in 2024, then plummeted by 34.48% to $55.9 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $55.9 million, $58.6 million, and $94.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.